PREVAIL: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

Trial Profile

PREVAIL: A Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy-Naive Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PREVAIL
  • Sponsors Medivation
  • Most Recent Events

    • 20 Jul 2017 Results of post-hoc exploratory analysis published in the Journal of Urology.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results (n=1709) of development (data cutoff June 1, 2014) and validation of a prognostic model for overall survival, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top